CoChat

Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion

Open access
Cortini, Margherita, Massa, Annamaria, Avnet, Sofia, Bonuccelli, Gloria, Baldini, Nicola · 2016 · PLOS ONE
Cited by 97

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Osteosarcoma (OS) is an aggressive bone malignancy with a high relapse rate despite combined treatment with surgery and multiagent chemotherapy. As for other cancers, OS-associated microenvironment may contribute to tumor initiation, growth, and metastasis. We consider mesenchymal stromal cells (MSC) as a relevant cellular component of OS microenvironment, and have previously found that the interaction between MSC and tumor cells is bidirectional: tumor cells can modulate their peripheral environment that in turn becomes more favorable to tumor growth through metabolic reprogramming. Here, we determined the effects of MSC on OS stemness and migration, two major features associated with recurrence and chemoresistance. The presence of stromal cells enhanced the number of floating spheres enriched in cancer stem cells (CSC) of the OS cell population. Furthermore, the co-culturing with MSC stimulated the migratory capacity of OS via TGFβ1 and IL-6 secretion, and the neutralizing antibody anti-IL-6 impaired this effect. Thus, stromal cells in combination with OS spheres exploit a vicious cycle where the presence of CSC stimulates mesenchymal cytokine secretion, which in turn increases stemness, proliferation, migration, and metastatic potential of CSC, also through the increase of expression of adhesion molecules like ICAM-1. Altogether, our data corroborate the concept that a comprehensive knowledge of the interplay between tumor and stroma that also includes the stem-like fraction of tumor cells is needed to develop novel and effective anti-cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0166500

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 49

  1. TS Park, 2014, Dynamic Interactions Between Cancer Stem Cells And Their Stromal Partners, Curr Pathobiol Rep, 2, 41, 10.1007/s40139-013-0036-5 · DOI · Paper page
  2. E Fessler, 2013, Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?, Cancer Lett, 341, 97, 10.1016/j.canlet.2012.10.015 · DOI · Paper page
  3. M Salerno, 2013, Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas, Int J Oncol, 43, 95, 10.3892/ijo.2013.1927 · DOI · Paper page
  4. CP Gibbs, 2005, Stem-like cells in bone sarcomas: implications for tumorigenesis, Neoplasia, 7, 967, 10.1593/neo.05394 · DOI · Paper page
  5. V Tirino, 2011, at al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo, FASEB J, 25, 2022, 10.1096/fj.10-179036 · DOI · Paper page
  6. V Desiderio, 2013, Molecular Profiling of Human Primary Chondrosarcoma-Derived Spheres Reveals Specific and Target Genes Involved in Multidrug Resistance and Metastasis, J Carcinogene Mutagene, 5, 1000152
  7. JN Cormier, 2004, Soft tissue sarcomas, CA Cancer J Clin, 54, 94, 10.3322/canjclin.54.2.94 · DOI · Paper page
  8. MS Isakoff, 2015, Osteosarcoma: Current Treatment and a Collaborative Pathway to Success, J Clin Oncol, 33, 3029, 10.1200/JCO.2014.59.4895 · DOI · Paper page
  9. A Longhi, 2006, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art, Cancer Treat Rev, 32, 423, 10.1016/j.ctrv.2006.05.005 · DOI · Paper page
  10. VO Lewis, 2007, What's new in musculoskeletal oncology, J Bone Joint Surg Am, 91, 1399, 10.2106/00004623-200706000-00030 · DOI
  11. W Xiao, 2013, Mesenchymal stem cell transformation and sarcoma genesis, Clin Sarcoma Res, 3
  12. SA Bergfeld, 2010, Bone marrow-derived mesenchymal stem cells and the tumor microenvironment, Cancer Metastasis Rev, 29, 249, 10.1007/s10555-010-9222-7 · DOI · Paper page
  13. A Uccelli, 2008, Mesenchymal stem cells in health and disease, Nat Rev Immunol, 8, 726, 10.1038/nri2395 · DOI · Paper page
  14. WH Huang, 2013, Mesenchymal stem cells promote growth and angiogenesis of tumors in mice, Oncogene, 32, 4343, 10.1038/onc.2012.458 · DOI · Paper page
  15. B Tu, 2014, Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway, Exp Cell Res, 320, 164, 10.1016/j.yexcr.2013.10.013 · DOI
  16. T Kishimoto, 2006, Interleukin-6: discovery of a pleiotropic cytokine, Arthritis Res Ther, 8, S2, 10.1186/ar1916 · DOI
  17. S Lemma, 2016, Identification and validation of housekeeping genes for gene expression analysis of cancer stem cells, Plos One, 11, e0149481, 10.1371/journal.pone.0149481 · DOI
  18. A Duperray, 1997, Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging, J Biol Chem, 272, 435, 10.1074/jbc.272.1.435 · DOI
  19. K Scotlandi, 1996, Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors, Am J Pathol, 149, 1209
  20. R Ferracini, 1995, The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit, Oncogene, 10, 739
  21. S Patanè, 2006, MET overexpression turns human primary osteoblasts into osteosarcomas, Cancer Res, 66, 4750, 10.1158/0008-5472.CAN-05-4422 · DOI · Paper page
  22. V Salvatore, 2015, Changes in the gene expression of co-cultured human fibroblast cells and osteosarcoma cells: the role of microenvironment, Oncotarget, 6, 28988, 10.18632/oncotarget.4902 · DOI
  23. B Hoesel, 2013, The complexity of NF-κB signaling in inflammation and cancer, Mol Cancer, 12, 86, 10.1186/1476-4598-12-86 · DOI · Paper page
  24. SY Kim, 2013, Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells, Cell Signal, 25, 961, 10.1016/j.cellsig.2013.01.007 · DOI · Paper page
  25. H Hov, 2009, c-Met signaling promotes IL-6-induced myeloma cell proliferation, Eur J Haematol, 82, 277, 10.1111/j.1600-0609.2009.01212.x · DOI · Paper page
  26. S Avnet, 2008, Increased osteoclast activity is associated with aggressiveness of osteosarcoma, Int J Oncol, 33, 1231
  27. Z Duan, 2002, Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells, Cytokine, 17, 234, 10.1006/cyto.2001.1008 · DOI
  28. CH Tang, 2011, IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells, J Biol Chem, 286, 11056, 10.1074/jbc.M110.204081 · DOI
  29. CW Lo, 2011, IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer, Cancer Res, 71, 424, 10.1158/0008-5472.CAN-10-1496 · DOI · Paper page
  30. ML Broadhead, 2011, The molecular pathogenesis of osteosarcoma: a review, Sarcoma, 2011, 959248, 10.1155/2011/959248 · DOI · Paper page
  31. L Postiglione, 2005, Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation, Int J Oncol, 26, 1193
  32. JI Park, 2003, Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways, Oncogene, 22, 4314, 10.1038/sj.onc.1206478 · DOI · Paper page
  33. L Song, 2012, TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets, J Clin Invest, 122, 3563, 10.1172/JCI62339 · DOI · Paper page
  34. S Xu, 2014, Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma, DNA Cell Biol, 33, 802, 10.1089/dna.2014.2527 · DOI
  35. LM Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 · DOI · Paper page
  36. D Di, 2016, Downregulation of human intercellular adhesion molecule-1 attenuates the metastatic ability in human breast cancer cell lines, Oncol Rep, 35, 1541, 10.3892/or.2016.4543 · doi:10.3892/or.2016.4543
  37. CH Hou, 2014, Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway, Biochem Pharmacol, 89, 453, 10.1016/j.bcp.2014.03.010 · DOI
  38. YM Lin, 2013, IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma, Cancer Lett, 328, 135, 10.1016/j.canlet.2012.08.029 · DOI
  39. HK Tsou, 2013, HGF and c-Met interaction promotes migration in human chondrosarcoma cells, PLoS One, 8, e53974, 10.1371/journal.pone.0053974 · DOI
  40. K Miekus, 2013, The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation, Cell Death Dis, 7, e459, 10.1038/cddis.2012.199 · DOI
  41. Y To, 2002, A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line, Am J Respir Cell Mol Biol, 27, 220, 10.1165/ajrcmb.27.2.4804 · DOI
  42. H Hov, 2009, c-Met signaling promotes IL-6-induced myeloma cell proliferation, Eur J Haematol, 82, 277, 10.1111/j.1600-0609.2009.01212.x · DOI · Paper page
  43. K Skrzypek, 2015, Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression, Oncotarget, 6, 31378, 10.18632/oncotarget.5145 · DOI
  44. YC Lim, 2014, C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell, Oral Oncol, 50, 633, 10.1016/j.oraloncology.2014.04.004 · DOI
  45. B Szewczyk, 2015, Targeting MET receptor in rhabdomyosarcoma: rationale and progress, Curr Drug Targets
  46. DR Hodge, 2005, The role of IL-6 and STAT3 in inflammation and cancer, Eur J ancer, 41, 2502, 10.1016/j.ejca.2005.08.016 · DOI · Paper page
  47. GB Park, 2015, Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents, Int J Oncol, 46, 185, 10.3892/ijo.2014.2721 · DOI
  48. Y Zhang, 2015, Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model, Oncotarget, 7, 446, 10.18632/oncotarget.6371 · DOI
  49. H Korkaya, 2011, Breast cancer stem cells, cytokine networks, and the tumor microenvironment, J Clin Invest, 12, 3804, 10.1172/JCI57099 · DOI · Paper page

Cited by

Metadata

Authors
Cortini, M., Massa, A., Avnet, S., Bonuccelli, G., & Baldini, N.
Venue
PLOS ONE
Published
2016-11-16
Volume
11
Issue
11
Pages
e0166500
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2551599370
Cited by
97
References
14
FWCI
4.48
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.